A message from our Chief Medical officer.
Dear valued patient,
We recognise there are a lot of concerns surrounding COVID-19, and we are writing to all our patients who are currently taking part in our clinical trials with further information.
Firstly, we want to thank you for continuing to work with us in order to continue these vital clinical research trials. Never has MeDiNova experienced such a crucial time for medical services, our national health services, research organisations, pharmaceutical companies, governments and the many other front line services to work together.
We want to assure you that the safety of our participants and staff is absolutely our highest priority. We are constantly monitoring all official guidelines and advice regarding COVID-19 and adapting our working practices accordingly. Everything we are doing and will do has the welfare of all our patients and staff at its heart.
MeDiNova is continuing to operate our clinics as usual so that we can monitor your safety, however, we have enhanced and adjusted several of our processes in accordance with public health authority and government guidelines to keep risks to our patients and staff as low as possible during this time. This includes:•
- Implementing a questionnaire to ensure that patients who are likely to have come into contact with COVID-19 are not brought into our clinics.
- Ensuring safe transport to and from our clinics to avoid public transport.•
- Additional time is allotted between patient visits to eliminate wait times.•
- Reduction and control of the number of people in our clinics at any one time.•
- Antiseptic products will be available to use on site. •
- MeDiNova staff will be taking universal precautions including wearing gloves, gowns, and masks wherever necessary,•
- All our offices and clinics are cleaned multiple times each day with approved antiviral cleaning products.•
Patients who require off-site procedures at local hospitals may be screened on entering the hospital (i.e. temperature taken, questionnaire to be completed) to ensure patients who fall into the ‘vulnerable’ category, that is – over the age of 70, or with an underlying health condition as defined by Public Health England and broadly all those who are offered the flu-jab each year, have precautions taken to keep them safe.
Overall, MeDiNova will adopt best practice across our work and go above and beyond what is required to keep everyone as safe as possible.
Our teams are here for you if you need advice or reassurance and we will update our website with further news when the need arises or the situation changes.
Once again, thank you from the whole team here at MeDiNova for your continuing support of these important medical trials.
Dr Essam Abdulhakim MBChB, MS, FCRS -
Chief Medical Officer and Managing Director MeDiNova UK